# FDA 483 - Aspire Houston Fertility Institute - February 06, 2020

Source: https://www.keypedia.com/records/483/aspire-houston-fertility-institute/298011ba-b30e-4c82-874e-e3c38f7e43ad

> FDA 483 for Aspire Houston Fertility Institute on February 06, 2020. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Aspire Houston Fertility Institute
- Inspection Date: 2020-02-06
- Product Type: other
- Office Name: Dallas District Office
- Summary: Aspire Fertility in Houston, TX was inspected from February 5-6, 2020, regarding its human reproductive tissue operations. The inspection revealed a significant lapse in donor screening procedures, specifically the failure to perform physical examinations for directed semen donors to screen for communicable disease agents. This indicates a potential risk related to the safety of human reproductive tissue.

## Related Officers

- [Erma Zaimova](https://www.keypedia.com/people/erma-zaimova/87da23ad-48bb-4096-9d8a-e8511c6b5c98)

Company: https://www.keypedia.com/companies/aspire-houston-fertility-institute/514ae73f-1298-4e40-b701-8b27e48a6293

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9